Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza A(H1N1) viruses, Germany, 2007-8

Euro Surveill. 2010 Feb 11;15(6):19483.

Abstract

During the influenza season 2007-8, the proportion of seasonal influenza A(H1N1) viruses resistant to the neuraminidase inhibitor oseltamivir increased worldwide. We conducted an investigation to compare patients infected with oseltamivir-resistant (ose-R) and oseltamivir- susceptible (ose-S) influenza A(H1N1) viruses regarding risk factors for resistance and the capability to transmit in the household setting. Within a cohort of 396 laboratory confirmed influenza patients from sentinel physicians we conducted a nested case-control study among patients infected with A(H1N1). Thirty patients in the cohort were infected with influenza B, none with influenza A(H3N2) and 366 with A(H1N1). Of the 366 A(H1N1) viruses 52 (14%) were ose-R. Demographic characteristics, oseltamivir exposure, travel history and outcome were not significantly different between ose-S and ose-R patients. Among 133 households in the nested case-control study, secondary household attack rates in households with ose-R cases and households with ose-S cases were similar (23 versus 26%; p-value=0.54). Ose-R household status and occurrence of secondary cases were associated with an odds ratio of 0.85 (95% confidence interval 0.38-1.88). We conclude that seasonal ose-R influenza A(H1N1) viruses have transmitted well in the household setting.

MeSH terms

  • Antiviral Agents / therapeutic use
  • Cohort Studies
  • Disease Outbreaks / statistics & numerical data*
  • Drug Resistance, Viral
  • Female
  • Germany / epidemiology
  • Housing / statistics & numerical data*
  • Humans
  • Incidence
  • Influenza A Virus, H1N1 Subtype*
  • Influenza, Human / drug therapy
  • Influenza, Human / epidemiology*
  • Influenza, Human / transmission*
  • Male
  • Oseltamivir / therapeutic use*
  • Risk Assessment
  • Risk Factors
  • Seasons*

Substances

  • Antiviral Agents
  • Oseltamivir